• 1
    Hoofnagle JH, Seeff LB. Peginterferon and ribavirin therapy of hepatitis C. N Engl J Med 2006; 355: 24442451.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 3
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 4
    Forestier N, Reesink H, Weeink C, McNair L, Kieffer T, Chu H-M, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. HEPATOLOGY 2007; 46.doi: 10.1002/hep.21774.
  • 5
    Kieffer T, Sarrazin C, Miller J, Welker M, Forestier NJ, Kwong A, et al. Telaprevir and pegylated interferon–alfa-2a inhibit wild-type and resistant genotype 1 HCV replication in patients. HEPATOLOGY 2007; 46.doi: 10.1002/hep.21781.
  • 6
    Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6: 316.
  • 7
    Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for the cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993; 67: 38353844.
  • 8
    Reesink HW, Zeuzem S, Weegink CJ, Forestier N, Van Vliet A, Van de Wetering de Rooij J, et al. Rapid decline in viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology 2006; 131: 9971002.
  • 9
    Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 1750817514.
  • 10
    Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004; 48: 47844792.
  • 11
    McHutchison JG, Everson GT, Gordon S, Jacobson I, Kauffman R, McNair L, et al. Results of an interim analysis of a phase 2 study of telaprevir (VX-950) with peginterferon alfa-2a and ribavirin in previously untreated subjects with hepatitis C [Abstract]. Available at:
  • 12
    Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44: 671678.
  • 13
    Novozhenov V, Zakharova N, Vinogradova E, Nikitin I, Gorbakov V, Yakovlev A, et al. Phase 2 study of omega interferon alone or in combination with ribavirin in interferon-naïve subjects with genotype-1 chronic hepatitis C [Abstract]. Gastroenterology 2007; 132(Suppl 2): A778.
  • 14
    Aora S, Xu C, Teng A, Peterson J, Yeh LT, Gish R, et al. Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. J Clin Pharmacol 2005; 45: 275285.
  • 15
    Marcellin P, Lurie Y, Rodrigues-Torres M, Chasen R, Xu Y, Murphy B. The safety and efficacy of taribavirin plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy-naïve patients infected with HCV: phase 3 results [Abstract]. J Hepatol 2007; 46(Suppl 1): S7.
  • 16
    Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 275279.
  • 17
    McHutchison JG, Bartenschlager R, Patel K, Pawlotsky J-M. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006; 44: 411421.
  • 18
    Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 12701278.
  • 19
    Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186189.
  • 20
    Pierra C, Amador A, Benzaria S, Cretton-Scott E, D'Amours M, Mao J, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′C-methylcytidine. J Med Chem 2006; 49: 66146620.
  • 21
    Lawitz E, Nguyen T, Younes Z, Santoro J, Gitlin N, McEniry D, et al. Clearance of HCV RNA with valopicitabine (NM283) plus peginterferon in treatment-naïve patients with HCV-1 infection: results at 24 and 48 weeks [Abstract]. J Hepatol 2007; 46(Suppl 1): S9.
  • 22
    Afdhal N, O'Brien C, Godofsky E, Rodriguez-Torres M, Pappas S, Lawitz E, et al. Valopicitabine (NM283), alone or with peginterferon, compared to peginterferon/ribavirin retreatment in patients with HCV-1 infection and prior non-response to peginterferon/ribavirin: final results [Abstract]. J Hepatol 2007; 46(Suppl 1): S5.